Epilepsy and Quinazolinones: The Renewable Relationship

Epilepsy is a global public health issue requiring a global response. Epilepsy is present everywhere and affects people of various ages, genders, ethnicities, and social backgrounds, regardless of geographical locations. Excess discharge from the cortical neurons in the cortical section of brain is generally responsible for epileptic state. Understanding the classification of epileptic seizures is the first step toward the correct diagnosis, treatment and prognostication of the condition. Specific seizure types or syndromes often respond better to specific medications or surgical approaches. Multidrug resistant syndrome and refractory epilepsy are the biggest challenge in treatment of epilepsy, they lead to defect access of Anti-Epileptic Drugs AEDs to their target in CNS. Moreover, the marketed drugs carry severe side effects such as drowsiness, hepatotoxicity, anemia, and teratogenicity. Therefore, there is pivotal need to discover more safe and effective drugs. Quinazolinones analogues represent molecules which are capable of binding at multiple sites with high affinity and facilitate more rapid discovery of useful medicinally active compounds. Series of new quinazolinone derivatives were synthesized by many sceintists around the world, screened virtually and evaluated for the anticonvulsant activity against different types of seizures. They are to be a vital part of the solution of epilepsy in the future.